S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:TROV - TrovaGene Stock Price, Forecast & News

$1.03
-0.04 (-3.74 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$1.01
Now: $1.03
$1.12
50-Day Range
$0.74
MA: $1.38
$2.18
52-Week Range
$0.70
Now: $1.03
$5.83
Volume80,977 shs
Average Volume598,514 shs
Market Capitalization$10.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.57
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
TrovaGene logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.94 per share

Profitability

Net Income$-16,410,000.00
Net Margins-3,688.31%

Miscellaneous

EmployeesN/A
Market Cap$10.52 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.


TrovaGene (NASDAQ:TROV) Frequently Asked Questions

How has TrovaGene's stock been impacted by COVID-19 (Coronavirus)?

TrovaGene's stock was trading at $1.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TROV shares have decreased by 7.2% and is now trading at $1.03. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TrovaGene.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for TrovaGene.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. TrovaGene had a negative net margin of 3,688.31% and a negative return on equity of 202.00%. View TrovaGene's earnings history.

When did TrovaGene's stock split? How did TrovaGene's stock split work?

Shares of TrovaGene reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TROV?

2 brokers have issued 12-month price objectives for TrovaGene's shares. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 1,307.8% from the stock's current price. View analysts' price targets for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. According to Zacks Investment Research, "Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. " (3/21/2020)
  • 2. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019)

Has TrovaGene been receiving favorable news coverage?

News coverage about TROV stock has trended very negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TrovaGene earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutTrovaGene.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Who are TrovaGene's key executives?

TrovaGene's management team includes the following people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

Who are TrovaGene's major shareholders?

TrovaGene's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.10%), LWS Wealth Advisors Inc. (2.02%), Prospera Financial Services Inc (0.41%) and Wedbush Securities Inc. (0.33%). Company insiders that own TrovaGene stock include Rodney S Markin and Stanley Tennant. View institutional ownership trends for TrovaGene.

Which institutional investors are buying TrovaGene stock?

TROV stock was purchased by a variety of institutional investors in the last quarter, including LWS Wealth Advisors Inc., Prospera Financial Services Inc, Wedbush Securities Inc., and Renaissance Technologies LLC. Company insiders that have bought TrovaGene stock in the last two years include Rodney S Markin, and Stanley Tennant. View insider buying and selling activity for TrovaGene.

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $1.03.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $10.52 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.  View additional information about TrovaGene.

What is TrovaGene's official website?

The official website for TrovaGene is http://www.trovagene.com/.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  697
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel